Results 181 to 190 of about 20,735 (212)

Update on Thromboembolic Events After Vaccination Against COVID-19. [PDF]

Vaccines (Basel)
Anastasiou T, Sanidas E, Lytra T, Mimikos G, Gogas H, Mantzourani M.   +5 more
europepmc   +1 more source

Longitudinal dynamics of humoral immune responses following serial COVID-19 vaccinations and breakthrough infections in dialysis patients. [PDF]

Hum Vaccin Immunother
Tsai WC, Chu FY, Chiu YL, Wu HY, Yang JY, Pai MF, Hsu SP, Tung KT, Shu KH, Lin WY, Peng YS.   +10 more
europepmc   +1 more source

COVID-19 breakthrough infections during the circulation of Delta and Omicron variants in Tirana, Albania, April 2021-March 2022. [PDF]

PLoS One
Konomi F, Bino S, Mersini K, Ramaj A, Danis K.   +4 more
europepmc   +1 more source

Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines. [PDF]

Commun Med (Lond)
Van Rampelbergh R, Pavord S, Anaya-Velarde L, van Paassen V, Hardt K, Tatar E, Ruiz-Guiñazú J, Baumgardner D, Oriol Mathieu V, Praet N, Kristyanto H, Sadoff J, Douoguih M, Xu Y, Struyf F.   +14 more
europepmc   +1 more source

Association between COVID-19 vaccination status and mortality in hospitalised COVID-19 patients during the Omicron period: a retrospective cohort study in Taiwan. [PDF]

BMJ Open
Chang MH, Ko SC, Liao KM, Ho CH.
europepmc   +1 more source

Reduced spike specific T-cell responses in COVID-19 vaccinated subjects undergoing SARS-CoV-2 breakthrough infection. [PDF]

Front Immunol
Varchetta S, Golfetto FS, Bono P, Callegaro A, Fabbris T, Favalli A, Crosti M, De Feo TM, Iannotti N, Bozzi G, Castelli V, Mariani B, Muscatello A, Abrignani S, Grifantini R, Bandera A, Lombardi A.   +16 more
europepmc   +1 more source

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

New England Journal of Medicine, 2021
Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca). More data were needed on the pathogenesis of this unusual clotting disorder.We assessed
Andreas Greinacher, Thomas Thiele, Theodore E Warkentin   +2 more
exaly   +7 more sources

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

New England Journal of Medicine, 2021
We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19). The patients were health care workers who were 32 to 54 years of age.
Nina Haagenrud Schultz, Ludvig A Munthe, Fridtjof Lund-Johansen   +2 more
exaly   +5 more sources